Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (14155)	11/16/2004 5:58:59 PM
From: tuck	Respond to of 52153

>>Was prevent II a single site study?<< It would appear so: biospace.com Assuming the following words aren't sloppy: "Dr. Grube and colleagues at The Heart Center in Siegburg . . . " Also found a bit of subset analysis here that looks decent, too: clinicalcardiology.org I'm referring to the data stratified by flow rate. But I wish they were still following these people. It's been pointed out that clinical issues get worse around five years for these patients. So far as I know, they were only followed for one year in the trials to date (don't know what's going on with PREVENT IV; found the protocol, but it has zero information). All I can find is some animal data -- which I've posted on the CGTK thread -- which could be extrapolated -- maybe. Cheers, Tuck